Transcriptome profiling of castration-resistant prostate cancer cells treated with novel androgen receptor (AR) and AR-V7 inhibitors

The purpose of this study was to characterize the downstream transcriptomic effects of ARVib-mediated degradation of AR/AR-V7, particularly in attenuating AR/AR-V7 target gene expression in prostate cancer cells. Towards this goal, next-generation sequencing (NGS)-based gene expression profiling (RNA-Sequencing; RNA-Seq) was performed on castration-resistant prostate cancer (CRPC) C4-2B MDVR cells that were treated with vehicle control or one of the AR/AR-V7 inhibitors (ARVib), ARVib-7 or ARVib-31. A total of 3 samples were analyzed in this study. The study focused on one castration-resisatnt prostate cancer (CRPC) cell line, LNCaP-C42B-MDVR. Individual cultures of LNCaP-C42B-MDVR were treated with DMSO vehicle control or one of the niclosamide analog AR/AR-V7 inhibitors (ARVibs ), ARVib-7 (analog #7) or ARVib-31 (analog #31). Following treatment of the cells for 24 hours, total RNA was isolated and then submitted for RNA-sequencing analysis.